middle.news
Chimeric Therapeutics Shows 75% Disease Control in Early CAR-T Trial
10:51am on Thursday 13th of November, 2025 AEDT
•
Healthcare
Read Story
Chimeric Therapeutics Shows 75% Disease Control in Early CAR-T Trial
10:51am on Thursday 13th of November, 2025 AEDT
Key Points
75% disease control at 28 days in evaluable patients
100% stable disease in patients at higher dose level
One colorectal cancer patient maintains stable disease nearly 1 year post-treatment
Phase 1/2 trial targets advanced gastrointestinal and neuroendocrine tumors
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CHM
OPEN ARTICLE